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The	growing	use	of	methods	to	measure	blood	pressure	(BP)		under	everyday	life	conditions	in	
“out-of-office”	settings,	through	either	24-hour	ambulatory	BP	monitoring	(ABPM)	or	home	BP	
monitoring	(HBPM),	for	defining	BP	status	has	led	to	identification	of	four	specific	hypertension	
phenotypes,	characterized	by	variable	agreement	or	disagreement	between	office	blood		pressure	
(OBP)	and	out-of-office	BP:	true	normotension	(normal	office	and	out-of-office	BP),	sustained	
hypertension	(both	elevated	office	and	out-of-office	BP),	masked	hypertension	(normal	office	BP	
and	out-of-office	BP),	and	white-coat	hypertension	(WCH),	when		OBP	is	elevated	but	out-of-office		
BP	levels	are	within	normal	limits	[1-2].	The	term	‘white-coat	hypertension’	is	probably	a	
misnomer	and	a	misconception,	because	it	does	not	necessarily	reflect,	or	at	most	partially,	an	
alerting	reaction	or	white-coat	effect	[3].	However,	the	suggestion	to	use	the	term	“isolated	office	
hypertension”	instead	of	the	more	appealing	“white	coat	hypertension”	has	not	gained	popularity	
in	clinical	practice	[2].	
The	definitions	of	WCH	and	masked	hypertension	(MHT)	originally	applied	to	people	who	were	not	
taking	antihypertensive	therapy.	However,	patients	on	antihypertensive	therapy	may	also	exhibit	
the	same	BP	measurement	pattern.	It	has	been	proposed	to	describe	discrepancies	between	office	
and	out-of-office	BP	in	patients	treated	for	hypertension,	with	the	terms	masked	uncontrolled	
hypertension	(MUCH)	(office	BP	controlled	but	home	or	ambulatory	BP	elevated)	and	white-coat	
uncontrolled	hypertension	(WUCH)	(office	BP	elevated	but	home	or	ambulatory	BP	controlled),	
compared	with	sustained	or	true	uncontrolled	hypertension	(SUCH)	(both	office	and	home	or	
ambulatory	BP	are	uncontrolled)	[1-2]	.	
Originally	the	definitions	of	WCH	and	MHT	were	based	on	clinic	BP	and	awake	or	24	h	ambulatory	
BP,	using	ABPM	as	the	method	to	assess	out-of-office	BP.	More	recently,	in	recognition	of	the	
prevailing	prognostic	value	of	night-time	BP	levels	over	other	components	of	the	24-hour	ABPM,	
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the	ESH	has	recommended	the	incorporation	of	night-time	BP	into	the	definition	of	WCH	and	MHT	
[1-2].	
Isolated	nocturnal	hypertension	(INH)	is	another	unique	phenotype	that	could	be	identified	by	the	
ABPM,	but	not	by	clinic	BP	measurement.	It	is	characterized	by	elevated	night-time	BP	(>120	
and/or	70	mmHg)	in	the	presence	of	normal	daytime	BP	[4].	When	this	condition	is	accompanied	
by	clinic	BP	values	in	the	normotensive	range,	INH	may	be	considered	a	subtype	of	masked	
hypertension,	that	can	be	defined	masked	nocturnal	hypertension,	in	untreated	subjects	or	
masked	uncontrolled	nocturnal	hypertension,	in	patients	treated	with	antihypertensive	drugs	[1,	
4-5].	
INH	was	first	described	in	2007	by	Li	et	al. as	novel	clinical	entity	characterized	by	elevated	night-
time	BP	(>120	and/or	70	mmHg)	in	the	presence	of	normal	daytime	BP	(<135/85	mmHg).		
	[4].	They	examined	a	Chinese	cohort	of	677	participants	enrolled	in	the	JingNing	population	study	
and	identified	INH	in	74	(10.9%)	individuals.	These	subjects,	compared	to	those	with	ambulatory	
normotension,	were	older,	more	often	reported	alcohol	intake,	had	faster	night-time	pulse	rate,	
had	higher	serum	cholesterol	and	blood	glucose	levels	[4].		
Only	5.4%	of	the	participants	with	INH	had	elevated	clinic	BP	in	this	cohort	study,	highlighting	the	
value	of	ABPM,	which	is	the	only	mean	by	which	a	diagnosis	of	INH	can	be	made	[4].	It	is	therefore	
largely	masked	because	of	the	limited	use	of	ABPM.	For	this	reason,	it	was	called	“a	disease	
masked	in	the	dark”	[5].	
The	prevalence	of	INH	was	reported	to	be	higher	(20.4	%)	in	a	population	of	1282	patients	with	
chronic	kidney	disease	(CKD)	admitted	to	a	Chinese	hospital	division	[6].	In	this	study	INH	was	
independently	associated	with	age,	estimated	glomerular	filtration	rate	and	clinic	diastolic	BP.		
The	frequency	and	clinical	characteristics	of	INH	were	recently	investigated	also	in	198	Japanese	
children	and	young	patients	with	CKD,	where	this	condition	was	detected	in	32	(16%)	subjects	[7].	
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A	similar	result	(13.4%)	was	more	recently	obtained	in	the	Cardiovascular	Comorbidity	in	Children	
with	Chronic	Kidney	Disease	Study,	a	cross-sectional	multicenter	cohort	investigation	conducted	in	
nearly	700	European	children	with	CKD.	
In	retrospective	analyses	of	the	International	Database	of		the	Ambulatory	Blood	Pressure	(IDACO)	
[5],	the	prevalence	of	INH	was	higher	among	South	Africans	of	black	ancestry	(10.2%)	and	
Japanese	(10.9%)	than	in	Western	(6.0%)	and	Eastern	(7.9%)	Europeans	[5].		
In	a	Swedish	study,	conducted	by	Wijkman	et	al.	[9]	in	414	middle-aged	patients		with	type	2	
diabetes,	30	(7.2%)	subjects	fulfilled	clinic	and	ambulatory	BP	criteria	for	masked	INH.		
In	the	Jackson	Heart	Study,	INH	was	found	in	about	one	fifth	of	the	entire	cohort	(19%)	[10].	
Individuals	with	INH	were	characterized	by	older	age,	higher	levels	of	total	and	LDL	cholesterol,	
and	higher	prevalence	of	type	2	diabetes	mellitus	than	counterparts	with	normal	BP	(19%	versus	
10%)	[10].		
Among	the	2021	subjects	enrolled	in	the	Pressioni	Monitorate	E	Loro	Associazioni	(PAMELA)	study,	
representative	for	gender	and	age	decades	of	the	population	of	Monza	in	Italy,	elevated	night-	
time	BP		and	normal	awake	BP	was	observed	in	11.4%	of	the	participants	[11].	Persons	with	INH	
had	many	features	of	the	metabolic	syndrome,	were	older	and	more	obese	than	the	normotensive	
participants	[11].	 
Data	from	the	Spanish	ABPM	Registry	showed	that	masked	uncontrolled	hypertension	was	very	
common	(37%),	most	often	because	of	poor	control	of	nocturnal	BP,	with	the	proportion	of	
patients	in	whom	MUCH	was	solely	attributable an	elevated	nocturnal	BP	almost	double	that	
solely	attributable	to	daytime	BP	elevation	(24.3	vs.	12.9%)	[12].	
The	study	of	Salazar	et	al,	published	in	the	current	issue	of	Journal	of	Hypertension	adds	a	new	
piece	of	evidence	in	this	scenario	[13].	The	aim	this	prospective	cohort	investigation	conducted		in	
Argentina,	was	to	assess	the	prevalence	of	INH	in	1344	patients	referred	to	perform	an	ABPM	for	
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diagnostic	or	therapeutic	purposes.	INH	was	detected	in	12.9	%	of	the	study	population.	Its	
prevalence	was	lower	in	subjects	with	office	hypertension	than	in	normotensive	ones	(7.4	vs.	
17.2%,	P<0.001)	and	similar	between	nonhypertensive	office	BP	categories	(optimal,	normal	and	
high-normal	BP)	[13].	Nocturnal	hypertension	was	the	more	prevalent	phenotype	of	masked	
hypertension	and	more	than	one-third	of	the	individuals	with	nocturnal	hypertension	had	INH.	In		
multivariate	analyses	the	independent	correlates	of	INH	were		only	age,	waist	and	neck	
circumferences.	It	is	important	to	note	that	the	chance	of	having	INH	was	unrelated	to	office	BP	
categories	[13].	This	finding	makes	the	identification	of	INH	more	difficult,	being	unrealistic	to	
perform	ABPM	in	all	normotensive	subjects.	
Even	if	the	findings	of	the	current	study	contribute	to	expand	our	knowledge	about	INH,	providing	
useful	insights		about	this	challenging	BP	phenotype,	some	weaknesses	must	be	acknowledged	
when	interpreting	its	results.		
	The	sleep	apnoea	syndrome	(SAS)	is		a	well-known	cause	of	nocturnal	BP	increase	[2].	Therefore,	
the	absence	of	polysomnographic	data,	as	well	as	not	having	used	validated	questionnaires	to	
screen	for	SAS,	such	as	the	Berlin	Questionnaire,	the	STOP-Bang,	or	the Epworth	Sleepiness	Scale	
may	be		limitations	of	the	current	study.		
The	long-	term	and	short-term	reproducibility	of	INH	has	been	reported		to	be	poor,	in	the	only	
two	investigations	exploring	this	issue	[4,	].		Unfortunately,	this	question	could	not	be	addressed	in	
the	study	of	Salazar	et	al,	because	participants	completed	only	one	ABPM.		
Available	evidence	supports	the	association	of	INH	with	an	increased	risk	of	CV	morbidity	and	
mortality.	In	a	multivariate	adjusted	analysis	of	the	data	from	over	8000	participants	from	three	
continents	in	the	IDACO	database,	INH	was	associated	with	a	higher	risk	of	all	cardiovascular	
events	(HR	1.38	[1.02–1.87];	p = 0.037)	and	total	mortality	(HR	1.29	[1.01–1.65],	p = 0.045),	as	
compared	to	nocturnal	normotension	[24]	More		recently,	in	a	total	of	588	Chinese	CKD	patients	
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multivariable	Cox	regression	analyses	showed	that	INH,	even	when	adjusted	for	clinic	BP,	24-hour	
BP,	or	daytime	BP,	was	associated	with	an	increased	risk	for	renal	events	(hazard	ratio	[HR],	3.81;	
95%	CI,	1.74–8.36)	and	cardiovascular	events	(HR,	8.34;	95%	CI,	1.98–35.07)	compared	with	
nocturnal	normotension.		
This	enhanced	risk	may	be	mediated	by	an	increased	prevalence	in	subjects	with	INH	of	
hypertension	mediated	organ	damage	(HMOD).	However,	the	studies	exploring	the	relationships	
between	INH	and	HMOD	yielded	conflicting	results	(Table	1)	[4-5,	8-11].	Controversy	also	exists	on	
the	question	which	blood	pressure	(BP)	pattern	–	isolated	daytime	or	nocturnal	hypertension	-	has	
greater	impact	on	HMOD.	In	this	regard,	the	study	of	Salazar,	cannot	provide	help,	because	
information	regarding	target	organ	damage	was	not	available	.	Therefore,	additional	research	are	
needed	to		elucidate	these	important	issues.		
Moreover,	future	investigations	should	assess		the	better	strategy	to	identify	subjects	with	masked	
INH	and	whether	or	not		targeting	INH by	planning	a	chronotherapeutic	approach	in	prospective	
studies	reduces	cardiovascular	events.	
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Table 1. Studies exploring the prevalence of isolated nocturnal hypertension (INH)  and of masked isolated nocturnal hypertension (MNH) and their 
relationships with some markers of target organ damage. 
 
é Increased in INH compared to true normotension; ê     Reduced  in INH compared to true normotension; 
=      No difference between INH and  true normotension; NA: Not assessed;  
PWV: pulse wave velocity; AoAix: Aortic Augmentation index; IMT: intima-media thickness; GFR: glomerular filtration rate; 
ECG-LVH: Left ventricular hypertrophy diagnosed by Electrocardiogram; ECHO-LVH: Left ventricular hypertrophy diagnosed by 
Echocardiogram. 
Authors, year [ref] N. of 
subjects 
Prevalence of INH 
(MNH) % 
Markers of hypertension mediated organ damage in INH compared to normotension 
PWV AoAIx Carotid IMT 
and plaques 
Estimated 
GFR 
Proteinuria ECG-
LVH 
ECHO-
LVH 
Li Y et al, 2007 [4] 677 10.7 (13.2)    é  = NA NA NA NA NA 
Wijkman	M	et	al,	2009	[9] 414 (7.2)  é  = NA = NA NA = 
Wang	M	et	al,	2015	[6] 1282 20.4   NA NA é ê NA NA NA 
Cuspidi C et al, 2017 [11] 2021 11.4   NA NA NA NA NA é é 
Fujita H et al, 2017 [7] 198 16 (8.1)   NA NA NA NA NA NA NA 
Düzova	A	et	al,	2019	[8] 688 13.4 (14.4)   é  é NA NA NA NA 
Ogedegbe	G	et	al,	2013	[10] 425 19.1   NA NA NA NA = NA = 
Li Y et al (International 
Database of Ambulatory 
Blood Pressure Monitoring), 
2007 [4]	
6038 
Overall: 7.7  
South Africa (Black): 
10.2   
Japan: 10.9  
Western Europe: 6  
Eastern Europe: 7.9  
NA NA NA NA NA NA NA 
Salazar	MR	et	al,	2019	[13]	 1344 12.9 % NA NA NA NA NA NA NA 
  
11 
11 
 
	
